Biotech firms commodify genetic data: 23andMe-HelthEx merger accelerates surveillance capitalism in healthcare, raising ethical and equity concerns
Original framing: “STAT+: 23andMe offers to connect users’ DNA data with medical records” — STAT News
The commodification of genetic data traces back to the eugenics movement of the early 20th century, which used 'scientific' justifications to pathologize marginalized groups. The 1996 Havasupai Tribe case, where Arizona State University misused genetic samples from Indigenous participants, set a precedent for corporate exploitation of biological data. The Human Genome Project's commercialization further institutionalized the privatization of genetic knowledge, paving the way for today's data surveillance capitalism. This merger is a continuation of these extractive patterns, not an innovation.
The 23andMe-HelthEx merger is not an isolated technological advancement but a symptom of a deeper systemic shift: the enclosure of biological life under corporate biopower.
This trend mirrors historical patterns of colonial extraction, from the Havasupai Tribe's exploitation to the Human Genome Project's commercialization, where marginalized communities bear the costs while corporations reap the profits. The merger's reliance on Eurocentric genetic databases and its disregard for indigenous data sovereignty perpetuate the very inequities it claims to address, reducing health to a transactional commodity. Yet, as the trickster Hermes reveals, this solemn narrative is riddled with absurdity—corporations claiming ownership over the code of life while communities suffer from preventable diseases. The solution lies in dismantling the extractive logic of surveillance capitalism and replacing it with models of communal governance, where biological data is treated as a shared resource, not a tradable asset. This requires not just regulatory reform but a cultural shift: one that centers indigenous epistemologies, decolonizes science, and redefines health as a collective responsibility rather than a corporate opportunity.